View ValuationNovozymes 향후 성장Future 기준 점검 3/6Novozymes (는) 각각 연간 14% 및 6.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 13.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 9% 로 예상됩니다.핵심 정보14.0%이익 성장률13.74%EPS 성장률Chemicals 이익 성장39.3%매출 성장률6.5%향후 자기자본이익률8.95%애널리스트 커버리지Good마지막 업데이트19 May 2026최근 향후 성장 업데이트공시 • Nov 06Novozymes A/S Revises Earnings Guidance for the Year 2025Novozymes A/S revised earnings guidance for the year 2025. For the year, the company expects organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in fourth quarter following favorable timing in third quarter. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%).공시 • May 08Novonesis A/S Maintains Earnings Guidance for the Year 2025Novonesis A/S maintained earnings guidance for the year 2025. For the year, company expected 5-8% organic sales growth (6-9% excluding the exit from certain countries).공시 • May 03Novonesis Provides Sales Guidance for the Year 2024Novonesis provided sales guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth.공시 • Mar 23Novonesis Provides Earnings Guidance for the Year 2024Novonesis provided earnings guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth.모든 업데이트 보기Recent updatesBoard Change • May 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Employee Representative Director Lars Koppler was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • Mar 24Novonesis A/S Approves Dividend on A and B ShareNovozymes A/S announced at the AGM held on March 23, 2026, approved distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share.공시 • Feb 27Novozymes A/S, Annual General Meeting, Mar 23, 2026Novozymes A/S, Annual General Meeting, Mar 23, 2026, at 16:00 Romance Standard Time. Location: gammel venlighedsvej 14, dk-2970 hoersholm, Denmark공시 • Feb 25+ 3 more updatesNovozymes A/S Proposes Dividend for Full Year 2025Novozymes A/S proposed dividend of DKK 4.25 per share. DKK 2.25 per share interim dividend paid August 27, 2025. 2025 pay-out ratio of 58.4% of adj. net profit.공시 • Nov 06Novozymes A/S Revises Earnings Guidance for the Year 2025Novozymes A/S revised earnings guidance for the year 2025. For the year, the company expects organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in fourth quarter following favorable timing in third quarter. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%).공시 • Aug 21+ 1 more updateNovonesis A/S Approves Interim Dividend for First Half of 2025Novozymes A/S approved an interim dividend of 2.25 DKK (EUR 0.30) approved for the first half of 2025.공시 • Jun 02Novonesis A/S (CPSE:NSIS B) completed the acquisition of remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR).Novonesis A/S (CPSE:NSIS B) agreed to acquire remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR) for €1.5 billion on February 11, 2025. Novonesis has reached an agreement with dsm-firmenich to dissolve the Feed Enzyme Alliance and take over its sales and distribution activities. The transaction is accretive to Novonesis' revenue growth, adjusted EBITDA margin and adjusted EPS excl. amortization, with attractive revenue synergies. dsm-firmenich expects to receive approximately €1.4 billion net in cash, after transaction costs and capital gains tax, and anticipates a book profit on the transaction to be recognized upon closing. Novonesis will continue a long-term commercial relationship with the Animal Nutrition & Health business, for the re-sale of its feed enzymes through the Animal Nutrition & Health world-class premix network. For the period ending December 31, 2024, Feed Enzymes Alliance of DSM-Firmenich AG reported total revenue of €300 million. Novonesis will continue the long-term supply relationship with DSM-Firmenich for their premix business. The acquisition is 100% debt financed and fully committed. The transaction is subject to regulatory approvals, the transaction is expected to close in the course of 2025. The expected strong cash generation will allow for deleveraging to the current target range of 1.3 to 1.7x net debt divided by EBITDA within the next 2 years. It is expected that the transaction will have no impact on dividend payouts. Gordon Dyal & Co acted as financial advisor, Baker McKenzie acted a legal advisor and financing is obtained through BNP Paribas to Novonesis. Piper Sandler acted as financial advisor to DSM-Firmenich AG. Novonesis A/S (CPSE:NSIS B) completed the acquisition of remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR) on June 2, 2025. All regulatory approvals have been achieved. Gregory Crookes, Stephanie Horowitz, Pieter Leefers, Chris In t Veld, Marc Besen, Jurre Jurriëns, Gunnar Sachs, Claudia Milbradt, Nicolas Hohn-Hein, Floris van de Bult, Florence Aubonnet, Wijnanda Rutten and Michiel Sunderman of Clifford Chance Partnerschaftsgesellschaft, Clifford Chance France and Clifford Chance LLP acted as legal advisor to DSM-Firmenich AG.공시 • May 08Novonesis A/S Maintains Earnings Guidance for the Year 2025Novonesis A/S maintained earnings guidance for the year 2025. For the year, company expected 5-8% organic sales growth (6-9% excluding the exit from certain countries).공시 • Apr 07Novonesis A/S to Report Fiscal Year 2025 Results on Feb 25, 2026Novonesis A/S announced that they will report fiscal year 2025 results on Feb 25, 2026공시 • Apr 05+ 1 more updateNovonesis A/S Approves Election of Monila Kothari as A Director and Composition of the Board of Directors and Its CommitteesNovonesis A/S at its Annual General Meeting held on April 3, 2025 approved election of Monila Kothari as a new member of the Board of Directors. Composition of the Board of Directors and its committees: After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees. The Board of Directors, including its committees, is now composed as follows: Cees (Cornelis) de Jong (Chair of the Board, chair of the Nomination and Remuneration Committee and member of the Audit Committee); Heine Dalsgaard (Vice Chair of the Board and member of the Audit Committee); Robert Nøddeskov Jensen (employee representative); Lise Kaae (chair of the Audit Committee); Monila Kothari (member of the Innovation Committee); Kasim Kutay (member of the Nomination and Remuneration Committee); Lars Bo Køppler (employee representative); Kevin Lane (member of the Innovation Committee); Preben Nielsen (employee representative and member of the Innovation Committee); Frederikke Rose Spenner (employee representative); Morten Otto Alexander Sommer (chair of the Innovation Committee) and Kim Stratton (member of the Nomination and Remuneration Committee).공시 • Mar 06Novonesis A/S Announces Board ChangesThe employees of Novonesis A/S have conducted the election of employee representatives to the Board of Directors of Novonesis (Novozymes A/S). The following employee representatives were elected for the next four years: Robert Nøddeskov Jensen, Senior Operator - newly elected. Lars Bo Køppler, Technician - newly elected and Frederikke Rose Spenner, Production Engineer - newly elected. As alternates to the employee representatives to the Board of Directors, the employees elected Mikael Barfred, Heidi Gelt and Ida Carlsen Virklund. The newly elected employee representatives will join the Board of Directors following the Annual General Meeting of Novonesis on April 3, 2025. At the same event, the term of election for the former employee representatives, Lena Bech Holskov, Anders Hentze Knudsen, and Jens Øbro will end. The term of Board Observer Kim Ib Sørensen will also end following the Annual General Meeting of Novonesis on April 3, 2025.공시 • Feb 26+ 2 more updatesNovonesis A/S Proposes Dividend, Payable on April 8, 2025Novonesis A/S proposed dividend of DKK 4.20 per share (EUR 0.56) with the total pay-out for the year unchanged compared to previous year. The dividend will be disbursed on April 8, 2025, with April 3, 2025, as the last trading day with dividend. Total dividend pay-out for the year equals 65.1% of the adjusted net profit.공시 • Feb 21Novonesis Announces Jacob Vishof Paulsen Will Leave His Position as Executive Vice President of Food & Beverage Biosolutions, Effective March 31, 2025Novonesis A/S announced that Jacob Vishof Paulsen will be leaving his position as Executive Vice President of Food & Beverage Biosolutions, as he has accepted a role outside of Novonesis, effective March 31, 2025. Jacob joined Chr. Hansen in 2006 and became a member of the Corporate Leadership Team in 2013. During his tenure in Chr. Hansen, Jacob has held multiple global sales and business unit leadership positions and since 2019 been responsible for the Food Cultures & Enzymes business unit, before entering his current role in Novonesis.공시 • Dec 17Novonesis A/S Announces That Sharon James Will Not Be Seeking Re-Election to the Board of Directors, Effectively on December 31, 2024Sharon James will not be seeking re-election to the Board of Directors of Novonesis at the upcoming annual general meeting in 2025 and will step down effectively on December 31, 2024. This decision reflects her desire to focus on personal priorities. Sharon James has expressed her gratitude for the opportunity to serve together with the Board and Management team with strong confidence in Novonesis’ future leadership and strategic vision.공시 • Nov 07+ 2 more updatesNovonesis A/S to Report First Half, 2025 Results on Aug 13, 2025Novonesis A/S announced that they will report first half, 2025 results on Aug 13, 2025공시 • Oct 21Novonesis A/S Announces Board ChangesNovonesis A/S announced that Anne Breum, one of the employee-elected members of the Board of Directors of Novozymes A/S, has decided to step down as a board member. The first alternate, Lena Bech Holskov (Safety Adviser, OHS) has replaced Anne Breum as employee-elected board member of the Company for the remaining period of the current four-year election term ending following the annual general meeting of the Company to be held on April 3, 2025.공시 • Aug 28Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024Novonesis approved interim dividend for 2024 at DKK 2.00 per share (EUR 0.27). The dividend will be disbursed on September 3, 2024, with August 29, 2024, as the last trading day with dividend.공시 • May 03Novonesis Provides Sales Guidance for the Year 2024Novonesis provided sales guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth.공시 • May 01Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023Novozymes A/S announced at the AGM held on April 30, 2024, approved distribution of profit with payment of an ordinary dividend of DKK 2.00 or EUR 0.27 per A/B share of DKK 2 for the last four months (September 1 - December 31) of 2023. Legacy Novozymes shareholders will then have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share, which equals an increase of 3% compared with 2022.공시 • Apr 09Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023Novozymes A/S announced that at its AGM to be held on April 30, 2024, The distribution of profit will be addressed at the meeting and the board of directors proposes an ordinary dividend of DKK 2 or EUR 0.27 per A/B share for the last four months (September 1 to December 31) of 2023. This equals a pay-out ratio of 53.2% of the company’s adjusted net profit for the four-month period. Following the approval of the proposed dividend, legacy Novozymes shareholders will have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share (50.8% pay-out ratio). This equals an increase in the paid dividend of 3% compared to the dividend paid for the 2022 result.공시 • Mar 23Novonesis Provides Earnings Guidance for the Year 2024Novonesis provided earnings guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth.공시 • Feb 24+ 3 more updatesNovozymes A/S to Report First Half, 2024 Results on Aug 28, 2024Novozymes A/S announced that they will report first half, 2024 results on Aug 28, 2024공시 • Jun 30Novozymes A/S, Annual General Meeting, Mar 13, 2024Novozymes A/S, Annual General Meeting, Mar 13, 2024.이익 및 매출 성장 예측BATS-CHIXE:NSISBC - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20285,0829639811,5021412/31/20274,7438478261,3801612/31/20264,4307327531,414153/31/20264,1995977741,282N/A12/31/20254,1585847511,222N/A9/30/20254,1425477451,123N/A6/30/20254,098565569918N/A3/31/20254,058459586950N/A12/31/20243,8343066601,020N/A9/30/20243,471314634941N/A6/30/20243,047283599891N/A3/31/20242,636334422692N/A12/31/20232,402406281557N/A9/30/20232,390430169485N/A6/30/20232,38246083436N/A3/31/20232,39048783476N/A12/31/20222,360494150539N/A9/30/20222,268460206554N/A6/30/20222,186418262539N/A3/31/20222,090416337530N/A12/31/20212,009423379546N/A9/30/20211,958427461593N/A6/30/20211,914409432564N/A3/31/20211,883389443577N/A12/31/20201,883380459585N/A9/30/20201,920415442521N/A6/30/20201,955405465536N/A3/31/20201,968439407482N/A12/31/20191,924422N/A428N/A9/30/20191,923411N/A460N/A6/30/20191,917434N/A505N/A3/31/20191,922417N/A477N/A12/31/20181,927432N/A493N/A9/30/20181,924427N/A515N/A6/30/20181,915429N/A490N/A3/31/20181,920423N/A501N/A12/31/20171,952419N/A546N/A9/30/20171,958421N/A533N/A6/30/20171,934412N/A522N/A3/31/20171,919414N/A547N/A12/31/20161,902410N/A517N/A9/30/20161,864394N/A488N/A6/30/20161,883394N/A437N/A3/31/20161,883384N/A450N/A12/31/20151,876378N/A447N/A9/30/20151,840366N/A395N/A6/30/20151,795353N/A443N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: NSISBC 의 연간 예상 수익 증가율(14%)이 saving rate(3.4%)보다 높습니다.수익 vs 시장: NSISBC 의 연간 수익(14%)이 UK 시장(11.4%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: NSISBC 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: NSISBC 의 수익(연간 6.5%)이 UK 시장(연간 4.5%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: NSISBC 의 수익(연간 6.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: NSISBC의 자본 수익률은 3년 후 9%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 21:36종가2026/05/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Novozymes A/S는 28명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Alexander SloaneBarclaysCezara LozneanuBarclaysSebastian SatzBarclays25명의 분석가 더 보기
공시 • Nov 06Novozymes A/S Revises Earnings Guidance for the Year 2025Novozymes A/S revised earnings guidance for the year 2025. For the year, the company expects organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in fourth quarter following favorable timing in third quarter. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%).
공시 • May 08Novonesis A/S Maintains Earnings Guidance for the Year 2025Novonesis A/S maintained earnings guidance for the year 2025. For the year, company expected 5-8% organic sales growth (6-9% excluding the exit from certain countries).
공시 • May 03Novonesis Provides Sales Guidance for the Year 2024Novonesis provided sales guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth.
공시 • Mar 23Novonesis Provides Earnings Guidance for the Year 2024Novonesis provided earnings guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth.
Board Change • May 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Employee Representative Director Lars Koppler was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • Mar 24Novonesis A/S Approves Dividend on A and B ShareNovozymes A/S announced at the AGM held on March 23, 2026, approved distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share.
공시 • Feb 27Novozymes A/S, Annual General Meeting, Mar 23, 2026Novozymes A/S, Annual General Meeting, Mar 23, 2026, at 16:00 Romance Standard Time. Location: gammel venlighedsvej 14, dk-2970 hoersholm, Denmark
공시 • Feb 25+ 3 more updatesNovozymes A/S Proposes Dividend for Full Year 2025Novozymes A/S proposed dividend of DKK 4.25 per share. DKK 2.25 per share interim dividend paid August 27, 2025. 2025 pay-out ratio of 58.4% of adj. net profit.
공시 • Nov 06Novozymes A/S Revises Earnings Guidance for the Year 2025Novozymes A/S revised earnings guidance for the year 2025. For the year, the company expects organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in fourth quarter following favorable timing in third quarter. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%).
공시 • Aug 21+ 1 more updateNovonesis A/S Approves Interim Dividend for First Half of 2025Novozymes A/S approved an interim dividend of 2.25 DKK (EUR 0.30) approved for the first half of 2025.
공시 • Jun 02Novonesis A/S (CPSE:NSIS B) completed the acquisition of remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR).Novonesis A/S (CPSE:NSIS B) agreed to acquire remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR) for €1.5 billion on February 11, 2025. Novonesis has reached an agreement with dsm-firmenich to dissolve the Feed Enzyme Alliance and take over its sales and distribution activities. The transaction is accretive to Novonesis' revenue growth, adjusted EBITDA margin and adjusted EPS excl. amortization, with attractive revenue synergies. dsm-firmenich expects to receive approximately €1.4 billion net in cash, after transaction costs and capital gains tax, and anticipates a book profit on the transaction to be recognized upon closing. Novonesis will continue a long-term commercial relationship with the Animal Nutrition & Health business, for the re-sale of its feed enzymes through the Animal Nutrition & Health world-class premix network. For the period ending December 31, 2024, Feed Enzymes Alliance of DSM-Firmenich AG reported total revenue of €300 million. Novonesis will continue the long-term supply relationship with DSM-Firmenich for their premix business. The acquisition is 100% debt financed and fully committed. The transaction is subject to regulatory approvals, the transaction is expected to close in the course of 2025. The expected strong cash generation will allow for deleveraging to the current target range of 1.3 to 1.7x net debt divided by EBITDA within the next 2 years. It is expected that the transaction will have no impact on dividend payouts. Gordon Dyal & Co acted as financial advisor, Baker McKenzie acted a legal advisor and financing is obtained through BNP Paribas to Novonesis. Piper Sandler acted as financial advisor to DSM-Firmenich AG. Novonesis A/S (CPSE:NSIS B) completed the acquisition of remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR) on June 2, 2025. All regulatory approvals have been achieved. Gregory Crookes, Stephanie Horowitz, Pieter Leefers, Chris In t Veld, Marc Besen, Jurre Jurriëns, Gunnar Sachs, Claudia Milbradt, Nicolas Hohn-Hein, Floris van de Bult, Florence Aubonnet, Wijnanda Rutten and Michiel Sunderman of Clifford Chance Partnerschaftsgesellschaft, Clifford Chance France and Clifford Chance LLP acted as legal advisor to DSM-Firmenich AG.
공시 • May 08Novonesis A/S Maintains Earnings Guidance for the Year 2025Novonesis A/S maintained earnings guidance for the year 2025. For the year, company expected 5-8% organic sales growth (6-9% excluding the exit from certain countries).
공시 • Apr 07Novonesis A/S to Report Fiscal Year 2025 Results on Feb 25, 2026Novonesis A/S announced that they will report fiscal year 2025 results on Feb 25, 2026
공시 • Apr 05+ 1 more updateNovonesis A/S Approves Election of Monila Kothari as A Director and Composition of the Board of Directors and Its CommitteesNovonesis A/S at its Annual General Meeting held on April 3, 2025 approved election of Monila Kothari as a new member of the Board of Directors. Composition of the Board of Directors and its committees: After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees. The Board of Directors, including its committees, is now composed as follows: Cees (Cornelis) de Jong (Chair of the Board, chair of the Nomination and Remuneration Committee and member of the Audit Committee); Heine Dalsgaard (Vice Chair of the Board and member of the Audit Committee); Robert Nøddeskov Jensen (employee representative); Lise Kaae (chair of the Audit Committee); Monila Kothari (member of the Innovation Committee); Kasim Kutay (member of the Nomination and Remuneration Committee); Lars Bo Køppler (employee representative); Kevin Lane (member of the Innovation Committee); Preben Nielsen (employee representative and member of the Innovation Committee); Frederikke Rose Spenner (employee representative); Morten Otto Alexander Sommer (chair of the Innovation Committee) and Kim Stratton (member of the Nomination and Remuneration Committee).
공시 • Mar 06Novonesis A/S Announces Board ChangesThe employees of Novonesis A/S have conducted the election of employee representatives to the Board of Directors of Novonesis (Novozymes A/S). The following employee representatives were elected for the next four years: Robert Nøddeskov Jensen, Senior Operator - newly elected. Lars Bo Køppler, Technician - newly elected and Frederikke Rose Spenner, Production Engineer - newly elected. As alternates to the employee representatives to the Board of Directors, the employees elected Mikael Barfred, Heidi Gelt and Ida Carlsen Virklund. The newly elected employee representatives will join the Board of Directors following the Annual General Meeting of Novonesis on April 3, 2025. At the same event, the term of election for the former employee representatives, Lena Bech Holskov, Anders Hentze Knudsen, and Jens Øbro will end. The term of Board Observer Kim Ib Sørensen will also end following the Annual General Meeting of Novonesis on April 3, 2025.
공시 • Feb 26+ 2 more updatesNovonesis A/S Proposes Dividend, Payable on April 8, 2025Novonesis A/S proposed dividend of DKK 4.20 per share (EUR 0.56) with the total pay-out for the year unchanged compared to previous year. The dividend will be disbursed on April 8, 2025, with April 3, 2025, as the last trading day with dividend. Total dividend pay-out for the year equals 65.1% of the adjusted net profit.
공시 • Feb 21Novonesis Announces Jacob Vishof Paulsen Will Leave His Position as Executive Vice President of Food & Beverage Biosolutions, Effective March 31, 2025Novonesis A/S announced that Jacob Vishof Paulsen will be leaving his position as Executive Vice President of Food & Beverage Biosolutions, as he has accepted a role outside of Novonesis, effective March 31, 2025. Jacob joined Chr. Hansen in 2006 and became a member of the Corporate Leadership Team in 2013. During his tenure in Chr. Hansen, Jacob has held multiple global sales and business unit leadership positions and since 2019 been responsible for the Food Cultures & Enzymes business unit, before entering his current role in Novonesis.
공시 • Dec 17Novonesis A/S Announces That Sharon James Will Not Be Seeking Re-Election to the Board of Directors, Effectively on December 31, 2024Sharon James will not be seeking re-election to the Board of Directors of Novonesis at the upcoming annual general meeting in 2025 and will step down effectively on December 31, 2024. This decision reflects her desire to focus on personal priorities. Sharon James has expressed her gratitude for the opportunity to serve together with the Board and Management team with strong confidence in Novonesis’ future leadership and strategic vision.
공시 • Nov 07+ 2 more updatesNovonesis A/S to Report First Half, 2025 Results on Aug 13, 2025Novonesis A/S announced that they will report first half, 2025 results on Aug 13, 2025
공시 • Oct 21Novonesis A/S Announces Board ChangesNovonesis A/S announced that Anne Breum, one of the employee-elected members of the Board of Directors of Novozymes A/S, has decided to step down as a board member. The first alternate, Lena Bech Holskov (Safety Adviser, OHS) has replaced Anne Breum as employee-elected board member of the Company for the remaining period of the current four-year election term ending following the annual general meeting of the Company to be held on April 3, 2025.
공시 • Aug 28Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024Novonesis approved interim dividend for 2024 at DKK 2.00 per share (EUR 0.27). The dividend will be disbursed on September 3, 2024, with August 29, 2024, as the last trading day with dividend.
공시 • May 03Novonesis Provides Sales Guidance for the Year 2024Novonesis provided sales guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth.
공시 • May 01Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023Novozymes A/S announced at the AGM held on April 30, 2024, approved distribution of profit with payment of an ordinary dividend of DKK 2.00 or EUR 0.27 per A/B share of DKK 2 for the last four months (September 1 - December 31) of 2023. Legacy Novozymes shareholders will then have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share, which equals an increase of 3% compared with 2022.
공시 • Apr 09Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023Novozymes A/S announced that at its AGM to be held on April 30, 2024, The distribution of profit will be addressed at the meeting and the board of directors proposes an ordinary dividend of DKK 2 or EUR 0.27 per A/B share for the last four months (September 1 to December 31) of 2023. This equals a pay-out ratio of 53.2% of the company’s adjusted net profit for the four-month period. Following the approval of the proposed dividend, legacy Novozymes shareholders will have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share (50.8% pay-out ratio). This equals an increase in the paid dividend of 3% compared to the dividend paid for the 2022 result.
공시 • Mar 23Novonesis Provides Earnings Guidance for the Year 2024Novonesis provided earnings guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth.
공시 • Feb 24+ 3 more updatesNovozymes A/S to Report First Half, 2024 Results on Aug 28, 2024Novozymes A/S announced that they will report first half, 2024 results on Aug 28, 2024
공시 • Jun 30Novozymes A/S, Annual General Meeting, Mar 13, 2024Novozymes A/S, Annual General Meeting, Mar 13, 2024.